Everything You Need to Know About Pharmacokinetics (absorption, distribution, metabolism, excretion) for Step 1

Pharmacokinetics is basically the question: “What does the body do to the drug?” On Step 1, this shows up everywhere—biostats-style curves, mechanistic “why did this patient get toxicity?” vignettes, and classic First Aid pearls (CYP inducers/inhibitors, first-pass effect, loading doses, renal clearance). If you can confidently reason through ADME (Absorption, Distribution, Metabolism, Excretion), you’ll stop memorizing random facts and start predicting what happens.

---

Big Picture: ADME + the Core Equations You Actually Need

Pharmacokinetics (PK) describes how drug concentration changes over time. The two most-tested parameters are:

• Volume of distribution ($V_d$) → where the drug “goes”
• Clearance (CL) → how fast the drug is removed
• Half-life ($t_{1/2}$) → how long drug sticks around

High-yield relationships (know these cold)

• Loading dose: $\text{Loading dose} = \frac{C_p \times V_d}{F}$
• Maintenance dose rate: $\text{Maintenance dose rate} = \frac{CL \times C_{ss}}{F}$
• Half-life: $t_{1/2} = \frac{0.693 \times V_d}{CL}$
• Steady state: reached in about 4–5 half-lives (for first-order kinetics)
• First-order kinetics: constant fraction eliminated per unit time
• Zero-order kinetics: constant amount eliminated per unit time (toxicity risk)

💡

First Aid cross-ref: Pharmacokinetics section (General Principles), including $V_d$, clearance, half-life, steady state, and zero-order elimination (classic “PEA”: phenytoin, ethanol, aspirin at high doses).

---

Absorption: Getting the Drug Into the Body

Definition

Absorption = movement of drug from site of administration into systemic circulation.

Mechanisms & key concepts

• Passive diffusion (most common): favors lipophilic, nonionized drugs
• Ion trapping: weak acids/bases cross membranes best in their nonionized form
• Transporters (clinically relevant):
  • P-glycoprotein (P-gp) efflux pump (limits absorption, increases excretion)

Weak acids/bases (Step 1 favorite)

Use Henderson–Hasselbalch logic without overcomplicating it:

• Weak acids (HA) are nonionized in acidic environments → better absorbed in stomach (conceptually)
• Weak bases (B) are nonionized in basic environments → better absorbed in intestine

Ion trapping clinical vignettes:

• “Drug accumulates in breast milk” → milk is slightly acidic → weak bases get trapped (ionized) there
• “Fetal drug accumulation” → fetal blood relatively more acidic → weak bases can be trapped

💡

First Aid cross-ref: General Principles—Pharmacokinetics (ionization, Henderson–Hasselbalch, ion trapping).

First-pass effect (high yield)

First-pass metabolism = drug absorbed from GI tract → portal circulation → liver → systemic circulation. This reduces bioavailability ($F$).

Classic drugs with big first-pass effect

• Nitroglycerin (sublingual avoids first pass)
• Many opioids (variable), propranolol (conceptually tested)

Bioavailability ($F$)

• IV: $F = 1$
• Oral: $F < 1$ due to incomplete absorption and/or first-pass metabolism

Table: Absorption buzzwords → what they imply

---

Distribution: Where the Drug Goes (and Why That Matters)

Definition

Distribution = reversible transfer of drug between blood and tissues.

Volume of distribution ($V_d$)

Think of $V_d$ as a story about where the drug is:

• High $V_d$: drug leaves bloodstream → distributes into tissues/fat
  • often lipophilic, less protein-bound, or sequestered in tissue
• Low $V_d$: drug stays in blood
  • often hydrophilic and/or highly protein-bound

Key equation $V_d = \frac{\text{amount of drug in body}}{C_p}$

Protein binding (very commonly tested)

• Albumin binds acidic drugs
• $\alpha_1$-acid glycoprotein binds basic drugs
• Only free (unbound) drug is:
  • pharmacologically active
  • able to cross membranes
  • filtered at the glomerulus

Clinical consequence:
If a highly protein-bound drug gets displaced → free fraction increases → increased effect/toxicity.

💡

Step-style example: Warfarin (highly albumin-bound) displaced → bleeding risk (often integrated with CYP interactions too).

BBB and special compartments

• BBB favors lipophilic drugs or those with transporters
• Inflammation (e.g., meningitis) can increase BBB permeability → higher CNS penetration of some antibiotics (Step 2-ish but fair game)

Distribution in pregnancy

• Increased plasma volume → can increase apparent $V_d$ for hydrophilic drugs (lower peak concentrations)
• Placental transfer favored by lipophilicity; fetal ion trapping can occur with weak bases

💡

First Aid cross-ref: Pharmacokinetics ($V_d$, protein binding) + Pregnancy physiology (often integrated).

---

Metabolism: Making Drugs More Water-Soluble (Usually)

Definition

Metabolism = enzymatic conversion of drugs, mainly in the liver, to facilitate excretion.

Phase I vs Phase II (must know)

Phase I (functionalization)

• Oxidation, reduction, hydrolysis
• Often uses CYP450
• Can:
  • inactivate drugs
  • activate prodrugs
  • create toxic metabolites

Phase II (conjugation)

• Glucuronidation, acetylation, sulfation, methylation
• Generally makes compounds more water-soluble and ready for excretion

💡

First Aid cross-ref: CYP450 Inducers/Inhibitors, Phase I/II reactions, and classic toxic metabolites (e.g., acetaminophen → NAPQI).

CYP450: the recurring villain/hero

This is where Step 1 loves to combine pharm with clinical stems (e.g., “started a new medication,” “now INR changed,” “unexpected pregnancy,” etc.).

Common CYP inducers (decrease levels of many drugs)

Often remembered by “rifampin, carbamazepine, phenytoin, phenobarbital, St. John’s wort”.

Clinical outcomes of induction:

• ↓ warfarin effect → ↓ INR → thrombosis risk
• ↓ OCP effectiveness → unintended pregnancy
• ↓ protease inhibitor levels → HIV treatment failure

Common CYP inhibitors (increase levels of many drugs)

Classic set includes:

• Cimetidine
• Macrolides (esp. erythro/clarithro)
• Azoles
• Protease inhibitors
• Grapefruit juice
• Isoniazid (often tested)

Clinical outcomes of inhibition:

• ↑ warfarin effect → ↑ INR → bleeding
• ↑ statin levels → myopathy/rhabdo (esp. simvastatin; Step 1 classic)
• ↑ benzo/opioid levels → sedation/respiratory depression

💡

First Aid cross-ref: the CYP table (inducers/inhibitors) is essentially a must-memorize box.

Hepatic extraction ratio (conceptual high yield)

Some drugs are flow-limited (high extraction): clearance depends on liver blood flow.
Others are capacity-limited (low extraction): clearance depends on enzyme function and protein binding.

Step-style application:
In severe heart failure (low hepatic perfusion), high-extraction drugs can accumulate.

Prodrugs (frequent test pattern)

• “Drug is inactive until metabolized by liver” → impaired hepatic function can reduce activation
  Examples commonly tested across curricula: enalapril → enalaprilat; clopidogrel activation via CYP (also relevant to inhibitors).

---

Excretion: How the Drug Leaves (Kidney is King)

Definition

Excretion = removal of drug from body (kidney, bile/feces, lungs, sweat, breast milk).

Renal excretion: the three processes

1. Glomerular filtration: only free drug is filtered
2. Proximal tubular secretion: active transport (can be saturated; competition occurs)
3. Distal tubular reabsorption: passive; depends on lipid solubility and ionization

💡

First Aid cross-ref: renal handling and ion trapping (classic tie-in with urine alkalinization).

Urine pH manipulation (classic board question)

• Weak acids (e.g., salicylates):
  • Alkalinize urine → drug becomes ionized → trapped in urine → ↑ excretion
  • Clinical: sodium bicarbonate for aspirin toxicity
• Weak bases:
  • Acidifying urine theoretically increases excretion, but this is rarely used clinically due to risks

Table: Toxicology tie-in for renal trapping

Biliary excretion & enterohepatic recirculation

Some drugs are excreted in bile and reabsorbed in the gut → prolongs half-life.

Step-style clue: “Drug effect lasts longer than expected; gut flora disruption decreases effect.”

• Antibiotics can reduce gut bacteria that deconjugate drugs → ↓ enterohepatic recycling (classically discussed with OCPs in teaching, though mechanisms are multifactorial)

Dialysis: when does it help?

Dialysis works best for drugs that are:

• low $V_d$ (stay in blood)
• low protein binding
• small, water-soluble

Step-style reasoning:
A highly lipophilic drug with high $V_d$ won’t be removed effectively.

---

Kinetics: First-Order vs Zero-Order (and Why Toxicity Happens)

First-order elimination (most drugs)

• Rate of elimination proportional to concentration
• A constant fraction removed per time
• Half-life is constant

Zero-order elimination (high yield list)

• A constant amount removed per time (enzymes saturated)
• Half-life increases as concentration rises (dangerous)

Classic zero-order agents (often taught as “PEA”):

• Phenytoin
• Ethanol
• Aspirin (at high doses)

💡

First Aid cross-ref: the elimination kinetics box is a frequent quick-hit question.

---

Clinical “Presentation” of Pharmacokinetics Problems (How It Shows Up on Exams)

PK doesn’t present like one disease—it presents like patterns:

1) “Unexpected toxicity after adding a new drug”

Think:

• CYP inhibition
• Protein-binding displacement
• Reduced renal clearance (AKI, CKD)

2) “Drug stopped working after new medication started”

Think:

• CYP induction
• Reduced absorption (e.g., chelation, altered pH—often Step 2, but conceptually Step 1)

3) “Need to reach therapeutic level quickly”

Think:

• Give a loading dose (depends on $V_d$)
• Then maintenance (depends on clearance)

4) “Takes forever to reach steady state”

Think:

• Long half-life: high $V_d$ and/or low CL
• Rule: 4–5 half-lives to steady state

---

Diagnosis: How to Interpret PK Graphs and Labs

Concentration–time curve essentials

• $C_{max}$ and $T_{max}$: rate/extent of absorption
• AUC (area under curve): total exposure; proportional to bioavailability for a given dose
• Clearance affects how quickly concentration declines
• $V_d$ affects peak concentration (larger $V_d$ → lower initial plasma concentration for same dose)

Therapeutic drug monitoring (TDM): why we measure levels

You measure drug levels when:

• narrow therapeutic index
• variable metabolism/excretion
• clear concentration–effect relationship

Commonly monitored in curricula:

• aminoglycosides, vancomycin
• digoxin, lithium
• antiepileptics (e.g., phenytoin)

---

Treatment: How PK Directs Management (Not Just Memorization)

When you see toxicity or treatment failure, the intervention is often PK-based:

• Stop the offending drug and/or the interacting agent
• Adjust dose for renal/hepatic impairment
  • renal failure → decrease maintenance dose or increase dosing interval for renally cleared drugs
  • liver failure → watch for decreased metabolism, decreased albumin (↑ free drug)
• Antidotes (toxicology overlap): sometimes guided by PK (e.g., urine alkalinization for salicylates)
• Hemodialysis when drug properties favor it (low $V_d$, low protein binding)

---

High-Yield Associations & “If You See This, Think That”

Quick association list

• High $V_d$ → tissue sequestration; needs higher loading dose
• Low $V_d$ → stays in plasma; dialysis more effective
• Low albumin (cirrhosis, nephrotic syndrome) → ↑ free fraction of acidic drugs → toxicity risk
• Enzyme induction → ↓ drug level (except prodrugs may increase activation)
• Enzyme inhibition → ↑ drug level → toxicity
• Renal failure → ↓ clearance → ↑ half-life → takes longer to reach steady state and higher risk of accumulation
• 4–5 half-lives → steady state (and ~97% elimination after ~5 half-lives)

Mini-table: PK lever → what it changes

---

First Aid Cross-Reference Map (What to Revisit After This)

Use this as a targeted checklist in First Aid (General Principles → Pharmacology):

• Pharmacokinetics: $V_d$, clearance, half-life, steady state, loading vs maintenance dosing
• Drug elimination kinetics: first-order vs zero-order (“PEA”)
• CYP450: major inducers and inhibitors + classic interactions (warfarin, OCPs, statins, protease inhibitors)
• Toxicology tie-ins: acetaminophen metabolism (NAPQI), salicylate toxicity (urine alkalinization), dialysis principles

---

Final Step 1 Takeaway

If you reduce pharmacokinetics to a few controllable dials—$F$, $V_d$, CL, and enzyme activity—most exam questions become logic puzzles instead of memory traps. When in doubt, ask:

1. Did the drug get in? (absorption, first-pass, $F$)
2. Where did it go? ($V_d$, protein binding)
3. How is it processed? (Phase I/II, CYP interactions)
4. How does it leave? (renal/biliary excretion, dialysis suitability)

That’s ADME—board-style and clinic-relevant.